Flamel Technologies Sa (FLML): Craig R Stapleton , director of Flamel Technologies Sa purchased 27,228 shares on May 13, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $9.23 per share for a total value of $250,891.30 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 16, 2016, Michael S Anderson (CEO) purchased 5,000 shares at $8.84 per share price.On Mar 22, 2016, Phillandas T. Thompson (officer ) purchased 10,000 shares at $11.10 per share price.Also, On Mar 21, 2016, Sandra L Hatten (Sr. VP, Quality & Reg Affairs) purchased 3,000 shares at $11.01 per share price.On Mar 16, 2016, Craig R Stapleton (director) purchased 100,000 shares at $10.39 per share price.
Flamel Technologies S.A. (ADR): On Friday, May 13, 2016 heightened volatility was witnessed in Flamel Technologies S.A. (ADR) which led to swings in the share price. The shares opened for trading at $8.89 and hit $9.6799 on the upside , eventually ending the session at $9.32, with a gain of 5.55% or 0.49 points. The heightened volatility saw the trading volume jump to 3,56,843 shares. The 52-week high of the share price is $26.09 and the company has a market cap of $384 M . The 52-week low of the share price is at $7.56.
Flamel Technologies SA is a pharmaceutical company. The Companys focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Companys products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR the lead product using the Companys Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate) a non-selective antagonist of Beta 1 Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.